Superworth908 Devices price to book ratio MASS
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 3.7×
- 5-year median
- 1.6×
- Against its 5-year history
- 86th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.5× to 8.8×
- Peer median
- 5.7×
908 Devices' price to book ratio is 3.7× as of Oct 23, 2026.
That is above its 5-year median of 1.6×, higher than on 86% of days in the last 5 years.
Over that time it ranged from 0.5× in Dec 2024 to 8.8× in Jun 2021.
The median for 4 diagnostics and research stocks of a similar size is 5.7×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.7× | 1.4× | 4.1× |
| 2025 | 1.4× | 0.6× | 2.2× |
| 2024 | 0.6× | 0.5× | 1.6× |
| 2023 | 2.1× | 1.0× | 2.1× |
| 2022 | 1.2× | 1.2× | 4.5× |
| 2021 | 5.9× | 5.3× | 8.8× |
Against its peers
Companies in Medical - Diagnostics & Research nearest 908 Devices' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| MASS908 Devices | 3.7× |
| NRCNRC Health | 74.1× |
| ICCCImmucell | 3.0× |
| CDNACareDx | 8.4× |
| VCYTVeracyte | 2.8× |
| Peer median | 5.7× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on 908 Devices
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.